Literature DB >> 24769274

A useful multi-analyte blood test for cerebrotendinous xanthomatosis.

Andrea E DeBarber1, Jenny Luo2, Roberto Giugliani3, Carolina F M Souza4, John Pei-Wen Chiang5, Louise S Merkens6, Anuradha S Pappu6, Robert D Steiner7.   

Abstract

OBJECTIVES: Cerebrotendinous xanthomatosis (CTX) is a rare genetic disorder of bile acid (BA) synthesis that can cause progressive neurological damage and premature death. Blood (normally serum or plasma) testing for CTX is performed by a small number of specialized laboratories, routinely by gas chromatography-mass spectrometry (GC-MS) measurement of elevated 5α-cholestanol. We report here on a more sensitive biochemical approach to test for CTX particularly useful for confirmation of CTX in the case of a challenging diagnostic sample with 5α-cholestanol that, although elevated, was below the cut-off used for diagnosis of CTX (10 μg/mL or 1.0 mg/dL). DESIGN AND METHODS: We have previously described liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) methodology utilizing keto derivatization to enable the sensitive quantification of plasma ketosterol BA precursors that accumulate in CTX. We have expanded this methodology to perform isotope dilution LC-ESI-MS/MS quantification of a panel of plasma ketosterol BA precursors, with internal standards readily generated using isotopically-enriched derivatization reagent.
RESULTS: Quantification of plasma ketosterol BA precursors (7α-hydroxy-4-cholesten-3-one, 7α,12α-dihydroxy-4-cholesten-3-one and 7α,12α-dihydroxy-5β-cholestan-3-one) in a single LC-ESI/MS/MS test provided better discrimination between a CTX-positive and negative samples analyzed (n=20) than measurement of 5α-cholestanol alone.
CONCLUSIONS: Quantification of plasma ketosterol BA precursors provides a more sensitive biochemical approach to discriminate between CTX negative and positive samples. A multiplexed LC-ESI-MS/MS test quantifying a panel of plasma ketosterols, with simple sample preparation, rapid analysis time and readily available internal standards, can be performed by most clinical laboratories. Wider availability of testing will benefit those affected with CTX.
Copyright © 2014 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bile acids; CYP27A1; Cerebrotendinous xanthomatosis; Cholestanol; Ketosterols

Mesh:

Substances:

Year:  2014        PMID: 24769274      PMCID: PMC4175980          DOI: 10.1016/j.clinbiochem.2014.04.017

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  14 in total

1.  Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis.

Authors:  P T Clayton; A Verrips; E Sistermans; A Mann; G Mieli-Vergani; R Wevers
Journal:  J Inherit Metab Dis       Date:  2002-10       Impact factor: 4.982

Review 2.  Cerebrotendinous xanthomatosis: clinical and biochemical evaluation of eight patients and review of the literature.

Authors:  M Kuriyama; J Fujiyama; H Yoshidome; S Takenaga; K Matsumuro; T Kasama; K Fukuda; T Kuramoto; T Hoshita; Y Seyama
Journal:  J Neurol Sci       Date:  1991-04       Impact factor: 3.181

3.  Cholestanol deposition in cerebrotendinous xanthomatosis. A possible mechanism.

Authors:  G Salen
Journal:  Ann Intern Med       Date:  1971-12       Impact factor: 25.391

4.  Four novel CYP27A1 mutations in seven Italian patients with CTX.

Authors:  G N Gallus; M T Dotti; A Mignarri; A Rufa; P Da Pozzo; E Cardaioli; A Federico
Journal:  Eur J Neurol       Date:  2010-10       Impact factor: 6.089

5.  Capillary gas chromatographic determination of cholestanol/cholesterol ratio in biological fluids. Its potential usefulness for the follow-up of some liver diseases and its lack of specificity in diagnosing CTX (cerebrotendinous xanthomatosis).

Authors:  B J Koopman; J C van der Molen; B G Wolthers; A E de Jager; R J Waterreus; C H Gips
Journal:  Clin Chim Acta       Date:  1984-03-13       Impact factor: 3.786

6.  Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid.

Authors:  V M Berginer; G Salen; S Shefer
Journal:  N Engl J Med       Date:  1984-12-27       Impact factor: 91.245

7.  Elevated cholesterol precursors other than cholestanol can also be a hallmark for CTX.

Authors:  M G M de Sain-van der Velden; A Verrips; B H C M T Prinsen; M de Barse; R Berger; G Visser
Journal:  J Inherit Metab Dis       Date:  2008-10-24       Impact factor: 4.982

8.  Assay of intermediates in bile acid biosynthesis using isotope dilution--mass spectrometry: hepatic levels in the normal state and in cerebrotendinous xanthomatosis.

Authors:  I Björkhem; H Oftebro; S Skrede; J I Pedersen
Journal:  J Lipid Res       Date:  1981-02       Impact factor: 5.922

9.  ESI-MS/MS quantification of 7alpha-hydroxy-4-cholesten-3-one facilitates rapid, convenient diagnostic testing for cerebrotendinous xanthomatosis.

Authors:  Andrea E DeBarber; William E Connor; Anuradha S Pappu; Louise S Merkens; Robert D Steiner
Journal:  Clin Chim Acta       Date:  2009-10-03       Impact factor: 3.786

10.  Fast atom bombardment mass spectrometry in the diagnosis of cerebrotendinous xanthomatosis.

Authors:  B Egestad; P Pettersson; S Skrede; J Sjövall
Journal:  Scand J Clin Lab Invest       Date:  1985-09       Impact factor: 1.713

View more
  7 in total

Review 1.  Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).

Authors:  Gerald Salen; Robert D Steiner
Journal:  J Inherit Metab Dis       Date:  2017-10-04       Impact factor: 4.982

2.  Familial variability of cerebrotendinous xanthomatosis lacking typical biochemical findings.

Authors:  Adam J Guenzel; Andrea DeBarber; Kimiyo Raymond; Radhika Dhamija
Journal:  JIMD Rep       Date:  2021-01-08

Review 3.  Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management.

Authors:  Shuke Nie; Guiqin Chen; Xuebing Cao; Yunjian Zhang
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

4.  c.1263+1G>A Is a Latent Hotspot for CYP27A1 Mutations in Chinese Patients With Cerebrotendinous Xanthomatosis.

Authors:  Jingwen Jiang; Guang Chen; Jingying Wu; Xinghua Luan; Haiyan Zhou; Xiaoli Liu; Zeyu Zhu; Xiaoxuan Song; Shige Wang; Xiaohang Qian; Juanjuan Du; Xiaojun Huang; Mei Zhang; Wei Xu; Li Cao
Journal:  Front Genet       Date:  2020-07-01       Impact factor: 4.599

Review 5.  An update on oxysterol biochemistry: New discoveries in lipidomics.

Authors:  William J Griffiths; Yuqin Wang
Journal:  Biochem Biophys Res Commun       Date:  2018-02-05       Impact factor: 3.575

6.  Developing an Enzyme-Assisted Derivatization Method for Analysis of C27 Bile Alcohols and Acids by Electrospray Ionization-Mass Spectrometry.

Authors:  Jonas Abdel-Khalik; Peter J Crick; Eylan Yutuc; Yuqin Wang; William J Griffiths
Journal:  Molecules       Date:  2019-02-07       Impact factor: 4.411

7.  Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments.

Authors:  Shingo Koyama; Yoshiki Sekijima; Masatsune Ogura; Mika Hori; Kota Matsuki; Takashi Miida; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-05-08       Impact factor: 4.928

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.